Karyopharm Therapeutics
KPTI
KPTI
50 hedge funds and large institutions have $19M invested in Karyopharm Therapeutics in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
8.2% more ownership
Funds ownership: 42.92% → 51.13% (+8.2%)
6% more funds holding
Funds holding: 47 → 50 (+3)
Holders
50
Holding in Top 10
–
Calls
$1.61M
Puts
$127K
Top Buyers
| 1 | +$2.54M | |
| 2 | +$422K | |
| 3 | +$369K | |
| 4 |
SAM
Silverback Asset Management
Chapel Hill,
North Carolina
|
+$302K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$294K |
Top Sellers
| 1 | -$587K | |
| 2 | -$101K | |
| 3 | -$95.1K | |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$88.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$43.2K |
